Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

119th Congress Introduced by Jim Banks and 11 co-sponsors

The bill reauthorizes and likely expands programs to accelerate ALS therapy development, review, and patient access while boosting collaboration and funding.

Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.

Summary of S 4472 — Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Purpose and intent

The bill is titled the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.

Its central aim is to reauthorize and potentially extend or enhance programs related to accelerating access to therapies for Amyotrophic Lateral Sclerosis (ALS) in the United States.

The legislation appears to respond to ongoing efforts to streamline development, review, approval, and patient access to ALS therapies.

Key provisions and changes (as introduced)

The bill authorizes continued support for programs that facilitate faster access to ALS treatments. While the exact statutory text is not provided here, typical elements of such reauthorization measures may include:

Extension of authority for specific agencies or programs that pilot accelerated review processes, real-world evidence use, or patient access pathways.
Provisions to promote collaboration among federal agencies, researchers, clinicians, patient groups, and industry to shorten timelines from development to patient access.
Funding authorizations or appropriations language to sustain program activities (subject to Senate appropriations processes).
Possible enhancements to patient eligibility criteria, enrollment pathways, or data collection requirements to monitor safety and effectiveness in a real-world setting.

Who is affected

ALS patients and caregivers who stand to benefit from faster access to promising therapies.

Researchers, clinicians, and pharmaceutical/biotech developers seeking accelerated pathways or clearer regulatory expectations.

Federal agencies involved in medical product development, review, and approval (e.g., FDA) and any partner agencies administering ALS-specific programs.

Stakeholders in patient advocacy, such as ALS associations and consortia, which often participate in expedited access initiatives.

Procedural and timeline aspects

Introduced in the Senate and referred to the Committee on Health, Education, Labor, and Pensions (HELP) on April 30, 2026.

Read twice and referred to the same committee on the same date, indicating the bill will undergo committee review, potential markups, and hearings before any floor consideration.

As a reauthorization bill, passage would typically extend or modify existing authorities, funding, or program mandates that are set to expire or be nearing expiration, followed by enactment through standard Senate and, if advanced, House processes and a presidential signature.

Supporting context and considerations

Co-sponsors include Senators Chris Coons and Lisa Murkowski, indicating bipartisan interest in advancing ALS therapy access.

The bill’s impact depends on the specific statutory text and funding levels enacted; key questions include:

What authorities are being reauthorized or expanded (e.g., accelerated review programs, compassionate use pathways, or patient access demonstrations)?
Any changes to funding duration, appropriations ceilings, or reporting requirements.
Safeguards for patient safety, data transparency, and post-approval surveillance.

If you’d like, I can tailor this summary to include hypothetical provisions commonly seen in ALS-access acceleration bills, or wait for the full text to provide a more precise, clause-by-clause analysis.